Virtual reality based attentional bias modification training for patients with obsessive-compulsive disorder: a feasibility study - Scorecard - MDSpire
Advertisement
Virtual reality based attentional bias modification training for patients with obsessive-compulsive disorder: a feasibility study
Clinical Scorecard: Feasibility Assessment of Virtual Reality-Based Attentional Bias Modification Training for Individuals with Obsessive-Compulsive Disorder
At a Glance
Category
Detail
Condition
Obsessive-Compulsive Disorder (OCD)
Key Mechanisms
Attentional bias modification (ABM) training using virtual reality (VR) to modulate attentional bias and alleviate symptoms.
Target Population
Patients with contamination-based OCD currently receiving pharmacotherapy.
Care Setting
Outpatient treatment setting.
Key Highlights
VR-ABM training was conducted twice weekly for four weeks.
Participants reported the VR-ABM program as appropriately challenging.
Moderate levels of obsessive-compulsive symptoms and anxiety were elicited during VR scenarios.
The study supports the feasibility of VR-ABM in OCD treatment.
Further investigation in larger trials is warranted.
Guideline-Based Recommendations
Diagnosis
Assessment of OCD symptoms and attentional bias.
Management
Consideration of adjunctive VR-ABM training alongside standard pharmacotherapy.
Monitoring & Follow-up
Follow-up on symptom changes and patient feedback post-intervention.
Risks
Potential for eliciting anxiety during VR scenarios.
Patient & Prescribing Data
15 patients with OCD receiving pharmacotherapy.
VR-ABM may enhance engagement and ecological validity compared to traditional ABM.
Clinical Best Practices
Utilize immersive VR environments for symptom provocation.
Implement structured multi-session training programs for better efficacy.
Monitor patient responses to VR-ABM for ongoing adjustments.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
